Chemistry Reference
In-Depth Information
REFERENCES
1. Saxena, V., Panicucci, R., Joshi, Y., and Garad, S. (2009) Developability assessment in
pharmaceutical industry: an integrated group approach for selecting developable candidates.
J.
Pharm. Sci.
, 98(6):1962-1979.
2. Venkatesh, S. and Lipper, R. (2000) Role of the development scientist in compound lead
selection and optimization.
J. Pharm. Sci.
, 89(2):145
154.
3. Sasseville, V.G., Lane, J.H., Kadambi, V.J., Bouchard, P., Lee, F.W., Balani, S.K., Miwa,
G.T., Smith, P.F., and Alden, C.L. (2004) Testing paradigm for prediction of development-
limiting barriers and human drug toxicity.
Chem.-Biol. Interact.
, 150(1):9-25.
4. Sun, D., Yu, L.X., Hussain, M.A., Wall, D.A., Smith, R.L., and Amidon, G.L. (2004)
In vitro
testing of drug absorption for drug developability assessment.
Curr. Opin. Drug Discov. Dev.
,
7(1):75-85.
5. Balani, S.K., Miwa, G.T., Gan, L.S., Wu, J.T., and Lee, F.W. (2005) Strategy of utilizing
in vitro
and
in vivo
ADME tools for lead optimization and drug candidate selection.
Curr. Top.
Med. Chem.
, 5(11):1033-1038.
6. Balbach, S. and Korn, C. (2004) Pharmaceutical evaluation of early development candidates:
the “100-mg approach.”
Int. J. Pharm.
, 275(1-2):1-12.
7. Huang, L.-F. and Tong, W.-Q. (2004) Impact of solid state properties on developability
assessment of drug candidates.
Adv. Drug Deliv. Rev.
, 56(3):321-332.
8. Kerns, E.H. and Di, L. (2002) Multivariate pharmaceutical profiling for drug discovery.
Curr.
Top. Med. Chem.
, 2(1):87-98.
9. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (2001) Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings.
Adv. Drug Deliv. Rev.
, 46(1-3):3-26.
10. Amidon, G.L., Lennernäs, H., Shah, V.P., and Crison, J.R. (1995) A theoretical basis for a
biopharmaceutic drug classi
cation: the correlation of
in vitro
drug product dissolution and
in vivo
bioavailability.
Pharm. Res.
, 12(3):413-420.
11. Connelly, P.R., Vuong, T.M., and Murcko, M.A. (2011) Getting physical to fix pharma.
Nat.
Chem.
, 3(9):692
-
695.
12. Accenture (2007)
InPursuit of HighPerformance: UnderstandingPharmaceutical Research and
Development Cost Drivers
. Available at
http://www.accenture.com/Microsites/rdtransformation/
Documents/PDFs/Accenture_In_Pursuit_of_High_Performance.pdf.
Accessed 17 December
2014
.
13. Caldwell, G.W., Ritchie, D.M., Masucci, J.A., Hageman, W., and Yan, Z. (2001) The new pre-
preclinical paradigm: compound optimization in early and late phase drug discovery.
Curr.
Top. Med. Chem.
, 1(5):353-366.
14. Thomson Reuters (2009)
CMR International 2009 Pharmaceutical R&D Factbook
.
15. Gardner, C.R., Walsh, C.T., and Almarsson, O. (2004) Drugs as materials: valuing physical
form in drug discovery.
Nat. Rev. Drug Discov.
, 3(11):926-934.
16. Kwong, A.D., Kauffman, R.S., Hurter, P., and Mueller, P. (2011) Discovery and development
of telaprevir: an NS3-4a protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Nat. Biotechnol.
, 29(11):993-1003.
-
